Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Journal of Alzheimer's Disease : JAD
Leonel E RojoRicardo B Maccioni

Abstract

We describe the interactions of two benzimidazole derivatives, astemizole (AST) and lansoprazole (LNS), with anomalous aggregates of tau protein (neurofibrillary tangles). Interestingly, these compounds, with important medical applications in the treatment of allergies and gastrointestinal disorders respectively, specifically bind to aggregated variants of tau protein and to paired helical filaments isolated from brains of Alzheimer's disease (AD) patients. These ligands appear to be a powerful tool to tag brain-isolated tau-aggregates and heparin-induced polymers of recombinant tau. The interactions of AST and LNS with tau aggregates were assessed by classical radioligand assays, surface plasmon resonance, and bioinformatic approaches. The affinity of AST and LNS for tau aggregates was comparatively higher than that for amyloid-beta polymers according to our data. This is relevant since senile plaques are also abundant but are not pathognomonic in AD patients. Immunochemical studies on paired helical filaments from brains of AD patients and surface plasmon resonance studies confirm these findings. The capacity of these drugs to penetrate the blood-brain barrier was evaluated: i) in vitro by parallel artificial membrane permeab...Continue Reading

Citations

Apr 12, 2013·Proceedings of the National Academy of Sciences of the United States of America·Yervand Eduard KarapetyanCorinne Ida Lasmézas
Mar 23, 2013·PloS One·Nahuai BadiolaPatrick Aloy
Apr 5, 2014·BioMed Research International·Munazah Fazal Qureshi, Sushil K Jha
Apr 17, 2015·TheScientificWorldJournal·Hiroyuki WatanabeHideo Saji
Jan 21, 2017·Journal of Medicinal Chemistry·Frederik J R RomboutsDieder Moechars
Jun 8, 2017·Journal of the American Geriatrics Society·Felicia C GoldsteinIhab Hajjar
Oct 25, 2014·European Archives of Psychiatry and Clinical Neuroscience·Britta HaenischMartin Scherer
Dec 15, 2016·Expert Opinion on Drug Discovery·Debby Van Dam, Peter Paul De Deyn
Aug 17, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yanyan KongJian Chen
Apr 14, 2018·Current Neuropharmacology·Maja PrzybyłowskaIwona Inkielewicz-Stepniak
Oct 19, 2011·Physical Chemistry Chemical Physics : PCCP·Alexander K BuellTuomas P J Knowles
Jan 23, 2014·Journal of Labelled Compounds & Radiopharmaceuticals·Tetsuro TagoYukitsuka Kudo
Jul 12, 2014·Current Neurology and Neuroscience Reports·Stephen N Gomperts
Jan 27, 2019·Current Medicinal Chemistry·Hayrettin Ozan GulcanIlkay Erdogan Orhan
May 31, 2019·Journal of Gastroenterology and Hepatology·Sun-Kyeong ParkJu-Young Shin
Feb 26, 2015·Pharmacological Reports : PR·Anil Kumar Ekavali
Jun 14, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Victor L Villemagne, Nobuyuki Okamura
Feb 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Chun-Fang XiaHartmuth C Kolb
Nov 22, 2019·European Journal of Clinical Pharmacology·Yun ZhangYehuan Sun
Feb 7, 2020·The Laryngoscope·Hannah KavookjianShannon Kraft
Jan 15, 2020·Journal of Cancer Survivorship : Research and Practice·Annelise A MadisonJanice K Kiecolt-Glaser
Jul 22, 2018·European Journal of Gastroenterology & Hepatology·Md Mohaimenul IslamYu-Chuan Jack Li
Jun 2, 2020·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Madhav DesaiPrateek Sharma
Oct 18, 2011·Expert Opinion on Drug Discovery·Wendy NobleDiane P Hanger
Feb 3, 2018·Nuclear Medicine and Molecular Imaging·Yoori ChoiDong Jin Kim
Jul 26, 2015·Cellular and Molecular Neurobiology·Cesar Augusto Dias de PaulaDaniel Carneiro Carrettiero
Apr 1, 2016·Molecular Imaging·Lieven DeclercqGuy Bormans
Nov 10, 2015·Nuclear Medicine and Molecular Imaging·Yearn Seong Choe, Kyung-Han Lee
Feb 22, 2017·Molecular Neurodegeneration·Laure Saint-AubertAgneta Nordberg
Dec 1, 2018·Nano Convergence·You Jung KangHansang Cho
Jan 10, 2017·Frontiers in Aging Neuroscience·Gloria Patricia Cardona-Gómez, Francisco Lopera
May 18, 2019·Current Alzheimer Research·Leonardo Guzman-MartinezLeonardo P Navarrete
Jan 22, 2019·Computational and Mathematical Methods in Medicine·Ying-Hwey Nai, Hiroshi Watabe
May 15, 2018·Neural Plasticity·Gloria Ortiz-GuerreroMauricio Orlando Nava Mesa
Aug 1, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sarah K YeoMitchell S Albert
Nov 20, 2016·Journal of Labelled Compounds & Radiopharmaceuticals·Ramesh NeelamegamGeorges El Fakhri
Oct 24, 2019·Mini Reviews in Medicinal Chemistry·Predrag DugalicEsma R Isenovic
Apr 25, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Salman Ul IslamYoung Sup Lee
Mar 19, 2021·Seizure : the Journal of the British Epilepsy Association·Chih-Sung LiangMu-Hong Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.